
Release date: 2026-03-09 15:31:13 Article From: Lucius Laos Recommended: 8
Entrectinib is a targeted therapy for solid tumors positive for NTRK gene fusions and ROS1-positive non-small cell lung cancer. Its price varies depending on the region, dosage specifications, and medical insurance policies. For specific market prices, please refer to hospitals or pharmacies. Some indications have been covered by medical insurance reimbursement. Patients must strictly follow their doctor's prescription and adjust their treatment plan based on individual circumstances.
Regional Differences: Pricing differs across regions such as China, the United States, and Europe. In some countries, the out-of-pocket cost after medical insurance reimbursement may be significantly lower.
Dosage and Treatment Course: The dosage may be adjusted based on the patient's weight, disease progression, and side effects, directly impacting the total cost.
Medical Insurance Policies: Some regions have included Entrectinib in their medical insurance coverage, with reimbursement rates around 50%-70%. However, this usually requires meeting specific indications (e.g., ROS1-positive advanced lung cancer) confirmed by genetic testing.
Lucius Pharmaceuticals Entrectinib must be taken under a doctor's guidance; do not adjust the dose or stop taking it yourself. Target confirmation through genetic testing is necessary before treatment. During treatment, liver function, electrocardiogram (ECG), and other indicators should be monitored regularly.
Common side effects include dizziness, fatigue, and constipation. In severe cases, heart problems or liver injury may occur, requiring immediate medical attention.
Some charitable organizations or pharmaceutical companies offer patient assistance programs. Eligible low-income patients can apply for help with medication costs.
It is recommended to consult medical institutions or oncology specialists for the latest prices, medical insurance policies, and medication purchasing channels. Avoid obtaining the medication through informal channels.
Please consult a professional doctor before taking this medication. Develop an individualized plan based on your condition, financial situation, and medical insurance coverage to ensure safe and effective treatment.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:1572025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3962024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:1492025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:1692025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:1502025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1812025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:1642025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:1592025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: